{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=21", "query": { "condition": "B-cell Lymphomas (Phase 1)", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1137, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T10:05:38.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00343798", "title": "A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Prolymphocytic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Childhood Lymphoblastic Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage II Childhood Lymphoblastic Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Childhood Lymphoblastic Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Childhood Lymphoblastic Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "ex-vivo umbilical cord blood expansion", "type": "OTHER" }, { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "45 Years", "sex": "ALL", "summary": "6 Months to 45 Years" }, "enrollment_count": 23, "start_date": "2006-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-02-11", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 4, "location_summary": "Duarte, California • Aurora, Colorado • Denver, Colorado + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00343798" }, { "nct_id": "NCT05336409", "title": "A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "R/R CD19-Positive B-Cell Malignancies", "Indolent Non-Hodgkin Lymphoma", "Aggressive Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "CNTY-101", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "Lymphodepleting Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Century Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-01-24", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Diego, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05336409" }, { "nct_id": "NCT04637763", "title": "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Relapsed Non Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Lymphoma", "B Cell Lymphoma", "B Cell Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "CB-010", "type": "GENETIC" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Caribou Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2021-05-26", "completion_date": "2025-09", "has_results": false, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04637763" }, { "nct_id": "NCT00082784", "title": "Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Nodal Marginal Zone Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Refractory Plasma Cell Myeloma", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Alvocidib Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2004-03", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 5, "location_summary": "Tampa, Florida • Pittsburgh, Pennsylvania • Charleston, South Carolina + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082784" }, { "nct_id": "NCT03778073", "title": "Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Non Hodgkin Lymphoma", "Richter's Transformation" ], "interventions": [ { "name": "Cosibelimab", "type": "DRUG" }, { "name": "Cosibelimab + Ublituximab + Bendamustine combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-04-17", "completion_date": "2022-08-01", "has_results": false, "last_update_posted_date": "2022-08-22", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 9, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 6 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03778073" }, { "nct_id": "NCT02700022", "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-10", "completion_date": "2017-08-18", "has_results": false, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 2, "location_summary": "Duarte, California • Chapel Hills, North Carolina", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hills", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02700022" }, { "nct_id": "NCT04450069", "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-cell Lymphomas", "Diffuse Large B Cell Lymphoma (DLBCL)", "Follicular Lymphoma (FL)", "Chronic Lymphocytic Leukemia (CLL)", "Marginal Zone Lymphoma (MZL)", "Mantle Cell Lymphoma", "Small Lymphocytic Lymphoma (SLL)", "Primary Mediastinal Large B Cell Lymphoma", "Transformed Follicular Lymphoma", "Waldenstrom Macroglobulinemia", "Lymphoplasmacytic Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "CLBR001 and SWI019", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Calibr, a division of Scripps Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-08-14", "completion_date": "2024-05-06", "has_results": false, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 8, "location_summary": "Duarte, California • San Diego, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04450069" }, { "nct_id": "NCT02268851", "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "TGR-1202", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-11", "completion_date": "2022-10", "has_results": true, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 5, "location_summary": "Monterey, California • Hartford, Connecticut • Brewer, Maine + 1 more", "locations": [ { "city": "Monterey", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02268851" }, { "nct_id": "NCT00265837", "title": "Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 72, "start_date": "2002-12", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265837" }, { "nct_id": "NCT04521231", "title": "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Cell Precursor Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 181, "start_date": "2021-01-04", "completion_date": "2029-05-25", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-15T10:05:38.242Z", "location_count": 13, "location_summary": "Clovis, California • Duarte, California • Chicago, Illinois + 10 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521231" } ] }